WO2009041026A1 - Cxcl10 production inhibitor - Google Patents

Cxcl10 production inhibitor Download PDF

Info

Publication number
WO2009041026A1
WO2009041026A1 PCT/JP2008/002634 JP2008002634W WO2009041026A1 WO 2009041026 A1 WO2009041026 A1 WO 2009041026A1 JP 2008002634 W JP2008002634 W JP 2008002634W WO 2009041026 A1 WO2009041026 A1 WO 2009041026A1
Authority
WO
WIPO (PCT)
Prior art keywords
cxcl10
production inhibitor
complement fragment
cxcl10 production
polypeptide
Prior art date
Application number
PCT/JP2008/002634
Other languages
French (fr)
Japanese (ja)
Inventor
Yuji Takeda
Mayumi Hidaka
Noriyuki Shiobara
Katsuya Hiraishi
Nobuhito Kashiwagi
Original Assignee
Jimro Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jimro Co., Ltd. filed Critical Jimro Co., Ltd.
Publication of WO2009041026A1 publication Critical patent/WO2009041026A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed is a prophylactic/therapeutic agent for a disease induced by the enhanced production of CXCL10. Specifically disclosed is a CXCL10 production inhibitor comprising, as an active ingredient, a complement fragment selected from iC3b and C4b, a polypeptide functionally equivalent to the complement fragment, or a partial peptide of the complement fragment or the polypeptide.
PCT/JP2008/002634 2007-09-25 2008-09-24 Cxcl10 production inhibitor WO2009041026A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007247962A JP2010280569A (en) 2007-09-25 2007-09-25 Cxcl10 production inhibitor
JP2007-247962 2007-09-25

Publications (1)

Publication Number Publication Date
WO2009041026A1 true WO2009041026A1 (en) 2009-04-02

Family

ID=40510931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/002634 WO2009041026A1 (en) 2007-09-25 2008-09-24 Cxcl10 production inhibitor

Country Status (2)

Country Link
JP (1) JP2010280569A (en)
WO (1) WO2009041026A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006063A3 (en) * 2012-07-02 2014-03-20 Medizinische Universität Wien Complement split product c4d for the treatment of inflammatory conditions
JPWO2017014201A1 (en) * 2015-07-17 2018-06-07 富士フイルム株式会社 Nitrogen-containing heterocyclic compounds
US10987349B2 (en) 2016-12-27 2021-04-27 Fujifilm Corporation Antitumor agent and bromodomain inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519479A (en) * 2000-01-10 2003-06-24 イノジェネティックス・ナムローゼ・フェンノートシャップ Human and parasite orphan receptor proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519479A (en) * 2000-01-10 2003-06-24 イノジェネティックス・ナムローゼ・フェンノートシャップ Human and parasite orphan receptor proteins

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006063A3 (en) * 2012-07-02 2014-03-20 Medizinische Universität Wien Complement split product c4d for the treatment of inflammatory conditions
US9944685B2 (en) 2012-07-02 2018-04-17 Medizinische Universität Wien Complement split product C4d for the treatment of inflammatory conditions
US10358468B2 (en) 2012-07-02 2019-07-23 Medizinische Universität Wien Complement split product C4d for the treatment of inflammatory conditions
JPWO2017014201A1 (en) * 2015-07-17 2018-06-07 富士フイルム株式会社 Nitrogen-containing heterocyclic compounds
US20190077761A1 (en) 2015-07-17 2019-03-14 Fujifilm Corporation Nitrogen-containing heterocyclic compound
EP3327004A4 (en) * 2015-07-17 2019-03-27 Fujifilm Corporation Nitrogen-containing heterocyclic compound
US10696637B2 (en) 2015-07-17 2020-06-30 Fujifilm Corporation Nitrogen-containing heterocyclic compound
US10987349B2 (en) 2016-12-27 2021-04-27 Fujifilm Corporation Antitumor agent and bromodomain inhibitor

Also Published As

Publication number Publication date
JP2010280569A (en) 2010-12-16

Similar Documents

Publication Publication Date Title
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2007095618A3 (en) Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
WO2007017135A3 (en) Process for the preparation of olmesartan medoxomil
MX341883B (en) Pharmaceutical composition for treatment and prevention of cancer.
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
WO2007117971A3 (en) Ocular allergy treatments
ATE554084T1 (en) N-HYDROXYACRYLAMIDE COMPOUNDS
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
UA96575C2 (en) Process for the preparation of olmesartan medoxomil
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007030360A3 (en) P13k inhibitors for the treatment of endometriosis
WO2006108682A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents
AU2010279892A8 (en) Humanized anti-amyloid-b oligomer antibody
EA200702336A1 (en) APPLICATION 24-NorUDK
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease
WO2009041026A1 (en) Cxcl10 production inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834148

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08834148

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP